<DOC>
	<DOCNO>NCT00370617</DOCNO>
	<brief_summary>Chronic hepatitis C virus ( HCV ) infection associate increase risk development type 2 diabetes HCV infection may promote insulin resistance , irrespective severity liver disease . Insulin resistance seem genotype specific may play role fibrogenesis chronic hepatitis C. In “ vitro ” model , increased level insulin may promote increase HCV replication . RATIONALE Decreased insulin resistance reduce hyperinsulinemia may facilitate efficacy anti-viral drug HCV replication .</brief_summary>
	<brief_title>Pegylated-Interferon Ribavirin Plus Metformin Treatment Chronic HCV Infection Insulin Resistance</brief_title>
	<detailed_description>Chronic hepatitis C virus ( HCV ) infection associate increase risk development type 2 diabetes HCV infection may promote insulin resistance , irrespective severity liver disease . - In patient HCV infection , increase fast insulin level associate presence serum HCV core , severity hepatic fibrosis decrease expression insulin receptor substrate ( IRS ) 1 IRS2 , central molecule insulin-signaling cascade . Down-regulation IRS1 IRS2 also observe HCV core-transgenic mouse liver HCV core-transfected human hepatoma cell . - High level tumor necrosis factor-alpha , act disturb tyrosine phosphorylation insulin receptor substrate-1 , may associate insulin resistance animal model HCV patient . Insulin resistance seem genotype specific may play role fibrogenesis chronic hepatitis C. - In patient infected genotype non-3 , insulin resistance associate degree fibrosis , rate fibrosis progression previous fail antiviral treatment . - Insulin resistance , fibrosis , genotype independent predictor response antiviral therapy chronic hepatitis C patient treat peginterferon plus ribavirin . A sustained virological response achieve 33 % patient genotype 1 insulin resistance compare 60 % genotype 1 patient without insulin resistance . - Insulin resistance associate 3-fold risk failure antiviral treatment patient genotype 1 In “ vitro ” model , increased level insulin may promote increase HCV replication . RATIONALE Decreased insulin resistance reduce hyperinsulinemia may facilitate efficacy anti-viral drug HCV replication . INDICATION Genotype 1 Chronic HCV hepatitis ( CHC ) associate insulin resistance ( IR ) . OBJECTIVES To compare efficacy safety Pegylated-Interferon Ribavirin plus metformin Pegylated-Interferon Ribavirin treatment naïve patient Genotype 1 Chronic HCV infection insulin resistance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . No previous antiviral treatment 2 . Persistently elevate alanine aminotransferase ( ALT ) quantifiable HCVRNA ( &gt; 2000 copies/ml ) 3 . Liver biopsy ( within 12 month ) consistent CHC without cirrhosis 4 . Compensated liver disease ( ChildPugh grade A ) 5 . Insulin resistance ( evaluate HOMAR OGTT ) 6 . Negative pregnancy test 1 . Type 2 Diabetes ( accord ADA criterion ) 2 . BMI &gt; 30 3 . Alcohol consumption &gt; 30 g/day 4 . Other form liver disease ( HBV , autoimmune , genetic ) , HIV infection . 5 . Anemia 6 . Psychiatric disease 7 . Thyroid disease poorly control 8 . Overt cirrhosis , hepatocellular carcinoma 9 . Significant cardiac , renal , pulmonary disease , seizures .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>therapy</keyword>
</DOC>